Pegfilgrastim lowers side-effects of chemotherapy.
Dinesh C
DC
Sharma
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D005334:Fever; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D007239:Infections; D015337:Multicenter Studies as Topic; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy*; D011092:Polyethylene Glycols; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012307:Risk Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim